Roche have announced it plans to extend its $4.3 billion bid for gene therapy company Spark Therapeutics. While the company has been unable to get enough votes from shareholders to secure the deal, it still plans on moving forward with its takeover plans.
The company's deadline of April 3 has been pushed back to May 2 as it has only received support from holders with 29.4 percent of Spark shares while it requires a majority.
According to Roche, it expects the deal to be completed by June. The company also announced that the review by the U.S. Federal Trade Commission has been taking more time than anticipated.
Read the Reuters report